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GENERAL INTRODUCTION 
Clostridium chauvoei is a species of anaerobic, spore 
forming bacteria that is the etiologic agent of a disease 
commonly referred to as "blackleg". Blackleg affects 
primarily cattle and sheep, and occurs in livestock producing 
areas throughout the world. The disease is characterized by a 
rapidly fatal course of muscle necrosis and toxemia. Animals 
affected are usually found dead without any clinical symptoms 
having been observed. No data documenting the economic 
losses caused by blackleg have been published, however, the 
disease is so prevalent in the United States that vaccines 
containing Clostridium chauvoei are the most frequently used 
in the cattle industry. 
In the United States, vaccine manufacturers are regulated 
by the United States Department of Agriculture's, Animal and 
Plant Health Inspection Service. To maintain a license, 
manufacturers are required to test a fraction of each serial 
of vaccine for potency using acceptable methods outlined in 
the Code of Federal Regulations . The current potency test for 
products containing c. chauvoei involves vaccinating guinea 
pigs with the test vaccines then injecting them with virulent 
c. chauvoei spores. Nonvaccinated control guinea pigs also 
receive the virulent challenge. 
Two paramount disadvantages are inherent to this test: 
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the high cost and, more importantly, the pain and suffering 
that is inflicted on live animals. Development of a suitable 
alternative potency test that measured the serological 
response of rabbits to protective immunogens of c. chauvoei 
would alleviate both drawbacks of the current test . Since 
clostridial vaccines are always marketed as combination 
products, containing fractions that must be assayed for 
potency in rabbits, no additional animals would be required to 
perform this type of c. chauvoei potency test. Before such an 
alternative test can be developed however, specific protective 
i mmunogens of C. chauvoei must be identified and 
characterized. 
The objective of this study was to i dentify, purify, and 
partially characterize protective proteinaceous immunogens 
from c. chauvoei cultures for potential use in a potency 
assay. 
Thesis Organization 
This thesis consists of an introduction, a literature 
review, a separate manuscript, a general summary, a list of 
references cited in the literature review, and an appendix. 
The masters candidate , Paul Joseph Hauer, is the senior author 
and principal investigator for the manuscript. 
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LITERATURE REVIEW 
Clostridium chauvoei 
Clostridium chauvoei was first described by Arloing, 
Cornevin, and Thomas1 in 1887 as the etiological agent of a 
rapidly fatal myonecrotic disease of cattle and sheep commonly 
referred to as blackleg. The organism was named in honor of 
Jean-Baptiste Auguste Chauvoei, a prominent nineteenth century 
French medical researcher who worked extensively with it in 
studies on infectious diseases . Clostridium chauvoei is an 
anaerobic, Gram positive, pleomorphic bacillus with 
peritrichous flagella . Cell dimensions are variable, 
particularly in older cultures, and typically range from 0.5 
to 1.7 µm in width by 1 . 6 to 9 . 7 µmin length . Cells are 
frequently swollen by central to subterminal oval spores . 2 
The organism is more fastidious than most other clostridia. 
It is a strict anaerobe that grows best i n media such as 
chopped meat or brain-heart infusion which contain complex 
peptides and is noted for producing large amounts of gas. It 
has a requirement for high levels of cysteine . 8 Clostridium 
chauvoei resembles c . septicum closely enough that some 
researchers have proposed that they be classified in a single 
species''15'6 • However several unique characteristics make them 
readily distinguishable . 7 
Culture filtrates of c . chauvoei contain an array of 
extracellular enzymes including: oxygen- stable hemolysin, 
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oxygen labile hemolysin, hyaluronidase, neuraminidase, and 
• 8 910 • deoxyribonucleases. " The oxygen-stable hemolysin, 
designated as a toxin is hemolytic and causes necrosis when 
injected intradermally into guinea pigs. 
Clostridium chauvoei can be found in the soil, water, and 
the intestinal tracts of many species of living and dead 
animals. The organism has been shown to persist in loam for 
up to 11 years, 11 and Barnes et al. 12 correlated occurrence of 
the disease to newly excavated soil. Likewise, the presence 
• 131' 
of C. chauvoei in aquatic habitats is well established. ' 
Blackleg 
The disease caused by c. chauvoei occurs commonly in 
livestock production areas throughout the world. Although 
cattle and sheep are most often affected, goats, swine, deer, 
mink, guinea pigs, and mice are also susceptible . 7'16 Outbreaks 
in freshwater fish causing high mortality have been 
documented, 13 and recently a paralytic-like disease in 
t . h h b . d . th h . . f t . 16 os ric es as een associate wi c. c auvoei in ec ion. 
Humans appear quite resistant since no cases of human 
infection or disease have been reported. The disease is most 
often characterized by a rapidly fatal necrotizing myositis. 
Typically, the lesions are located in the large muscle masses 
of the fore- and hindquarters, hence the name "blackleg" or 
"blackquarter". The disease progresses swiftly and affected 
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animals are often found dead with no prior clinical signs. 
Early disease manifestations include elevation in temperature 
and marked swelling at the site of the lesion. In sheep the 
infection usually results from wound contamination, but in 
cattle there is often no evidence of trauma. Clostridium 
chauvoei has been isolated from spleens and livers of normal 
cattle17 suggesting entry via the hepatoportal pathway. Muscle 
and liver tissue may be seeded with viable organisms, possibly 
spores, which remain dormant until the environment is altered 
in some way to permit growth. The disease has been reproduced 
in animals by oral administration of organisms followed by an 
intramuscular injection of either saponin18 or calcium 
chloride. 19 Entry of the organism via the alveoli when 
deciduous teeth are lost has also been proposed.~ This 
hypothesis is supported by the fact that young cattle, 6 
months to 2 years old, are most often affected. However, 
cases of blackleg have also been reported in neonates21 and in 
utero . ~ Attack rates are usually quite low, but case fatality 
rates approach 100%.~ 
Gross lesions observed with blackleg are usually quite 
characteristic. Typically the affected muscles are blackened, 
dry, and crepitant with a rancid odor. A pale yellow fluid 
which eventually becomes bloodstained surrounds the lesion. 
Myocarditis and pericarditis or "blackleg of the heart" has 
also been described in both cattle and sheep. 2'.26 Malone et 
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al. 28 reported finding pericarditis in 48% of 29 cases, and the 
pericardium was the primary focus of infection in 21% of these 
cases. A single case of purulent meningitis in a calf was 
described from which a pure culture of c. chauvoei was 
obtained. 
Diagnosis of blackleg usually involves analysis of the 
history, clinical signs, and postmortem lesions. Culture 
results alone are not reliable for diagnosing clostridial 
infections due to the fastidious nature of some species, 
including C. chauvoei. The rapidity with which clostridia 
invade the tissues from the gastro-intestinal tract after 
death may also complicate diagnosis. 27 Batty et al. 28 suggested 
the criteria necessary for a diagnosis of clostridial 
infection should include analysis of the clinical picture, 
post mortem lesions, and state of decomposition of the animal. 
A fluorescent antibody staining technique is the most widely 
used diagnostic procedure to demonstrate clostridial species 
. 1 . 29 in esions. The utility of this method was demonstrated by 
Williams~ who was able to demonstrate the presence of 
C. chauvoei in 97 cases of suspected blackleg using 
fluorescent antibody staining while culturing the organism 
from only 89 of those cases. 
Treatment of the disease is usually futile, but has been 
successful with parenteral administration of high levels of 
antibiotics in conjunction with drainage and H202 lavage of 
7 
affected tissues.M 
Immunity to Blackleg 
Humoral immunity is considered most important in 
protecting an animal from infection with c. chauvoei. Oxer et 
al., 82 demonstrated that lambs from vaccinated ewes were 
passively protected against challenge by colostral antibodies. 
An in vitro plate agglutination assay~ was used to demonstrate 
maternally derived anti-c. chauvoei antibody in newborn 
M M ~ calves, ewes, and buffaloes. Macheak et al. used the plate 
agglutination assay to correlate antibody level to protection 
in cattle vaccinated with vaccines of varying potency. Awad 
et al. 87 demonstrated a correlation between agglutination 
titers and protection in guinea pigs and sheep. Passive 
protection has also been demonstrated using immune serum. 
Data from mice which were administered varying doses of immune 
equine serum revealed that maximum protection against 
challenge was afforded the mice receiving the largest doses.M 
Other researchers demonstrated passive protection in mice 
which were administered rabbit antibody directed specifically 
at the flagella of c. chauvoei. 89 In related experiments, 
Tamura and Tanaka'°·'1 showed that cyclophosphamide treatment of 
mice that had been administered anti-flagellar rabbit serum 
dramatically increased the fatality rate caused by a 
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c. chauvoei challenge, while treatment with carrageenan did 
not affect the fatality rate at all . This led to the 
conclusions that anti-flagellar serum exerts its protective 
effect by opsonic activity, and polymorphonuclear neutrophils 
are more important effector cells than macrophages in 
protection against the organism . Recently, a monoclonal 
antibody has been described which recognizes an epitope 
located on the surface of c. chauvoei flagella and also 
. 1 t . ' 2 passive y pro ects mice. 
Research into the relationship between cell-mediated 
immune responses and immunity to blackleg is limited. One 
study showed that neither delayed hypersensitivity nor 
leukocyte migration inhi bition could be detected in vaccinated 
guinea pigs prior to challenge, even though all of the animals 
were protected against challenge . ~ Aggluti nation titers in 
these protected guinea pigs were at high levels. In another 
study, cobra venom was used to deplete the CJ component of the 
complement system in subsequently challenged mice . " It was 
concluded that CJ did not play a significant role in the 
resistance of mice against c. chauvoei infection. 
The Protecti ve Antigens of c. chauvoei 
Vaccination for the prevention of blackleg has been 
practiced for over 100 years . Arloing, Cornevin, and Thomas 
prepared the first blackleg vaccine in 1881 , before the 
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causative agent had been isolated and identified. Early 
vaccines were prepared by heating or drying muscle tissue from 
infected animals. A later version of the vaccine commonly 
ref erred to as "aggressin" was prepared by collecting and 
filtering edema fluid from lesions. As one would expect from 
such crude preparations, local and systemic reactions were 
common side effects of vaccination. 7 In 1925, Lechlainche and 
Vallee~ showed that formalinized whole culture was an 
effective immunizing agent, and that form of vaccine was soon 
widely used by cattle producers. Blackleg vaccines currently 
licensed in the United States consist of formalinized whole 
cultures, differing little from the 1925 version. 
Immunity to blackleg is generally considered to involve 
antigens other than toxins • .a,•7 This is in contrast to the 
other common clostridial pathogens of animals in which 
protective immunity is equated to the level of specific toxin 
neutralizing antibody. 
The first work which identified individual antigens in 
'8 c . chauvoei was done by Roberts who devised a typing scheme 
based on heat stable somatic (0) and heat labile f lagellar (H) 
antigens. He concluded that the O antigen was common to all 
strains, but the H antigens of ovine and bovine isolates were 
unique. Henderson'9 later proposed that only English ovine 
isolates possessed a unique H antigen. This was confirmed by 
Moussa' who also demonstrated a spore antigen which was common 
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to all c. chauvoei and c. septicum isolates. KerryM confirmed 
an immunological difference between strains and concluded that 
animals showed a greater resistance to challenge by the 
homologous strain than by heterologous strains. 
Studies which tried to identify the specific protective 
immunogens of c. chauvoei have resulted in controversy and 
contradictions. Henderson50 was the first to demonstrate 
protection using boiled whole cells and reported that 
protection was due to the heat stable somatic o antigen. 
Subsequently the presence of protective antigen was 
demonstrated in culture supernatant . 61 That work has since 
been confirmed independently by several researchers. 62.M~• 
However, the relative contribution to immunity made by soluble 
immunogens remains unclear. The protective soluble immunogen 
is most likely proteinaceous since it can be precipitated with 
ammonium sulphate and is destroyed by treatment with trypsin, 
pepsin, hydrochloric acid, or heat.MM A purified soluble 
antigen has been described as being non- lethal to mice and 
distinct from an oxygen-stable hemolysin (a toxin). This 
soluble antigen was approximately twice the molecular weight 
of the a toxin, however it did elicit anti-hemolysin titers 
when injected into rabbits. This raised the possibility that 
a larger soluble immunizing agent dissociates into the 
hemolytic alpha toxin which is not capable of stimulating 
protective immunity.M M In contrast, Bergman reported that the 
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hemolysin of c. chauvoei was capable of inducing protective 
immunity, and the level of hemotoxoid in a vaccine correlates 
to the immunizing power of the vaccine. Hemolysin of 
c. chauvoei has recently been partially characterized, but its 
ability to induce protective immunity has not been 
determined. 66'157 
Many years after the early investigations on cellular 
antigens, attention was focused on flagella as a possible 
protective immunogen when it was reported that a highly 
protective strain of c. chauvoei differed from less protective 
strains only in flagellar antigen type. The observation was 
also made that the degree of cross-reactivity between O 
antigens was constant between strains regardless of their 
protective abilities and sera from highly protected guinea 
pigs failed to show O agglutination with either homologous or 
heterologous strains. These findings cast some doubt on the 
importance of the common heat stable o antigen as an 
immunizing agent in whole culture vaccines.~ In a subsequent 
investigation, flagella from c. chauvoei were purified using a 
procedure which included treatment with trypsin and sodium 
159 dodecyl sulfate. A flagellar preparation produced in this 
manner was not protective, but it did stimulate high 
agglutination titers when injected into rabbits. Conversely, 
def lagellated cells induced no measurable agglutination titers 
but were protective.M It was also demonstrated that 
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protoplasts of c. chauvoei were not protective but 
spheroplasts maintained protective antigenicity. 61 The 
conclusion from these studies was that the protective 
antigenicity of c. chauvoei was not of flagellar origin, but 
due to a heat labile, pH sensitive, non-agglutinogenic somatic 
antigen, possibly the peptidoglycan component of the cell 
wall.fil 
Despite the preceding findings, recent investigations 
into the protective immunogens of c. chauvoei have focused on 
flagella. Clostridium chauvoei anti-flagellar antibody, both 
monoclonal and polyclonal, have been shown to protect mice 
against challenge. A partially purified c. chauvoei flagellar 
preparation was shown to be 100-fold more protective in mice 
than a non-flagellated mutant strain.~ The protective effect 
of antisera against whole cells and partially purified 
flagella was lost after absorption with the parent strain, but 
no loss was shown after absorption with the non-flagellated 
mutant strain. 89 An acid extract antigen which possessed many 
characteristics of flagella was also shown to be highly 
protective in guinea pigs.~ Data from another study, however, 
showed no protection from homologous challenge when guinea 
pigs were immunized with acid extracted flagellar antigen . ~ 
Sanousi et al.~ tried to resolve the apparent discrepancy 
between protection induced by f lagellar vs somatic antigens by 
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growing c. chauvoei cultures in media of varying pH. More 
flagella were observed in cultures grown at pH 7.3, and 
vaccines containing equal numbers of cells provided greater 
protection when more flagella were present. The authors 
noted, however that somatic antigen may also have been 
influenced by pH changes . 
Investigators have cited various factors which may 
contribute to contradictions in these studies designed to 
identify protective immunogens. Some purification procedures 
may have been better than others in maintaining the native 
conformation of the antigens under investigation. Strain 
differences may also have played a role in the conflicting 
results. It appears likely that multiple antigens contribute 
to the protective immunogenicity of C. chauvoei and the 
relative contribution of each antigen may depend on the strain 
of both the immunizing agent and challenge. 
Assaying the Potency of C. chauvoei Vaccines 
The current standard for assaying the potency of 
C. chauvoei vaccines is a guinea pig protection test. 66'67 Host 
animal challenges have been conducted successfully in both 
cattle~ and sheep,~ and correlation to the guinea pig model 
has been established. Results of the guinea pig assay can be 
influenced by factors including the strain and diet of the 
guinea pigs. 69 Comparison of responses to vaccination between 
14 
guinea pigs and hamsters led to the observation that hamsters 
are immunized more readily by the cellular antigens and guinea 
pigs by the soluble antigens. Therefore, the two animal 
70 
species cannot be used interchangeably in protection tests. 
Mice are less suited to serve as a laboratory models because 
they appear to have some degree of natural immunity to 
c. chauvoei . 39'71 
Initial attempts to monitor the serological response of 
animals to C. chauvoei vaccines were directed at quantitating 
t . b d . th 1 t . t . 72 an i o y wi an agg u ina ion assay . While this test 
appeared to correlate to animal protection tests, difficulties 
were encountered with autoagglutination . A later version of 
the agglutination test which used washed, formalinized whole 
SS cells as the antigen was proposed by Claus and Macheak. This 
test also demonstrated strong correlation to animal protection 
tests, but controversy over the protective ability of 
f lagellar antigen precluded widespread acceptance since the 
test primarily measured flagellar antibody . 73 A flocculation 
assay, was developed to measure the level of protective 
7' antibody in sheep sera. The purpose of this test, however, 
was for selection of negative sheep for challenge studies and 
for use as a diagnostic a i d, not for potency testing vaccines. 
Several other assay procedures for c. chauvoei vaccines 
have been proposed. An indirect hemagglutination assay in 
which sonicated antigen, mainly of flagellar origin, was 
15 
adsorbed to treated red blood cells demonstrated good 
. f. 't 76 spec1 1c1 y. A strong correlation between results of this 
test, the agglutination assay, and a mouse protection test was 
established. 76 Results from an enzyme-linked immunosorbent 
assay (ELISA) which used culture filtrate as the solid phase 
antigen to quantitate the antibody response of vaccinated mice 
were shown to parallel the results obtained in a mouse 
77 protection assay. Another ELISA which used whole culture as 
the solid phase antigen also correlated with the guinea pig 
t t . 78 pro ec ion test. However, the specificity of the test was 
not addressed. Specificity is important since cross-
reactivity between clostridial antigens from different species 
has been frequently observed. 6•79•80 
Flagella as Immunogens and Test Antigens 
Flagella are major antigenic determinants in many 
bacteria and have been identified as virulence factors in some 
species such as Vibrio cholerae, Campylobacter jejuni, and 
Salmonella typhimurium. 81 The motility imparted to bacteria by 
flagella is important in establishing infections. For 
example, motility in Treponema pallidum, the etiological agent 
of venereal syphilis, has been shown to contribute to its 
ability to invade host tissue. 82 Antibodies to the flagella of 
Pseudomonas aeruginosa have been shown to be passively 
16 
protective, and non-motile variants exhibited reduced 
virulence in animal models.~ Also, aflagellate variants of 
Helicobacter pylori were, in contrast to flagellate organisms, 
unable to colonize the gastric mucosa of gnotobiotic piglets.~ 
Evidence suggests flagella may also act as adhesins, thus 
influencing pathogenesis in ways other than through motility.M 
Even the direction of flagellar rotation relative to the 
bacterial cell has been shown to influence pathogenicity in 
Salmonella typhimurium.~ 
Flagellar antigens frequently exhibit species or even 
strain specificities making them attractive antigens for use 
in diagnostic tests. Enzyme-linked immunosorbent assays using 
purified flagellar antigen have been described for diagnosis 
of congenital syphilis, 87 Tyzzer's disease,~ and Lyme 
b 1 . . 89,90 orre 1os1s. In each of these three cases, the specificity 
and sensitivity of the diagnostic test was enhanced when 
flagellar antigen was used in place of whole cell antigens. 
17 
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INTRODUCTION 
Clostridium chauvoei is the etiological agent of a 
disease commonly referred to as "blackleg." Blackleg most 
commonly affects cattle and sheep and is characterized by a 
necrotizing myositis, which is rapidly fatal. Vaccination for 
prevention of this and other clostridial diseases is routinely 
practiced with the use of multivalent bacterin-toxoids. 
Humeral immunity has been shown to be the major defense 
against infection with c. chauvoei1~, and passive immunity 
transfer through colostrum and immune serum has been 
demonstrated. M 
Specific protective antigens of c. chauvoei have not been 
well characterized. Both cellular and soluble antigens have 
been shown to elicit a protective immune response in guinea 
pigs5'6 , but controversy exists as to which specific antigens 
are responsible. Chandler and Gulasekharam7 reported that the 
protective cellular antigenicity of c. chauvoei was not of 
flagellar origin but due to a heat-labile, pH sensitive, 
nonagglutinogenic, somatic antigen. In contrast, Tamura et 
al. 8 used a partially purified flagellar preparation and a 
non-flagellated mutant to show that flagella were important 
for protective immunity in mice. Flagella-specific monoclonal 
antibodies which are passively protective in mice have also 
9 been produced . 
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The protective antigens present in the supernatant of 
c. chauvoei cultures also remain ambiguous. 10 Bergman reported 
that the hemolysin of c. chauvoei, designated as a toxin, was 
capable of inducing protective immunity. Bergman stated that 
level of hemotoxoid in a vaccine correlates to the immunizing 
power of the vaccine. 11 An investigation by Verpoorte et al. , 
however, revealed that purified hemolysin was poorly 
protective but a larger molecule, which itself was not 
hemolytic, could induce protective immunity and high 
antihemolysin titers. This led to speculation that an 
important soluble protective antigen for C. chauvoei was a 
molecule which dissociated into hemolysin. Claus et al. 12 also 
studied the immunizing properties of culture filtrate but made 
no attempt to separate individual protein antigens. 
Many of the antigens contained in a multivalent 
clostridial bacterin-toxoid are cross-reactive between 
species, 18'14 making the development of a serological potency 
test to evaluate the c. chauvoei fraction difficult. The 
objective of this investigation was to identify and purify 
specific protein antigens of c . chauvoei which are capable of 
eliciting a protective immune response in guinea pigs. 
Identification of specific protective antigens may facilitate 
development of a serological test that could be used in place 
of the current guinea pig challenge for assaying the potency 
of c. chauvoei bacterins. 
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MATERIALS AND METHODS 
Bacterial Strains 
Clostridium chauvoei, IRP 206 was used for preparation of 
all antigens as well as spore challenge in this experiment. 
CUlture Methods 
The culture medium consists of 55.5 g/l of dehydrated Brain 
Heart Infusion (BHI) and 3.5 ml/l of a 25% glucose solution in 
0 . 01 M phosphate buffered saline (PBS), pH 7.2. Dialysis 
tubing (12-14 Kd) containing 200 ml of 0 . 01 M PBS was 
suspended in the BHI, and the solutions were allowed to 
equilibrate overnight in an anaerobic incubator. Four ml of a 
c. chauvoei culture, which was actively growing in liver-egg-
brain medium, was inoculated into the dialysis tube . The 
culture was incubated anaerobically at 37°C. After 22 hours, 
the cells were harvested from the dialysis tubing and pelleted 
by centrifugation at 20,000 x g for 30 minutes. The pellet 
was resuspended in sterile saline containing 0.5% formalin and 
stored overnight at 4°C . Cells were then removed from the 
formalin solution by centrifugation at 9000 x g for 30 
minutes. The pellet was resuspended in 0.1 M Tris buffer, pH 
8.0. 
22 
Soluble Antigen 
Separation of the Soluble Protein Antigens 
The supernatant was added to an equal volume of saturated 
ammonium sulfate solution to precipitate the soluble protein. 
One mM EDTA and 1 µM leupeptin were added, and the solution 
was stored overnight at 4°C. The precipitated proteins were 
removed from the culture supernatant by centrifugation at 
15,000 x g for 30 minutes. The pellets containing the 
precipitated proteins were resuspended in sterile water, 
placed in dialysis tubing, and dialyzed against deionized 
water. Concentrated protein from the soluble phase of 3 
liters of culture grown in this manner was combined after 
dialysis, and the volume was increased to 50 ml with the 
addition of deionized water. Two ml of carrier ampholyte, pH 
gradient 4-6, was added to the protein solution. The solution 
was placed in a preparative isoelectric focusing chamber for 
2.5 hours at 12 watts . Twenty fractions were harvested, and 
the pH of each was recorded. The solutions were adjusted to 
neutral using either NaOH or HCl. Eighty µl of each fraction 
was boiled with sodium dodecyl sulfate (SOS) for 3 minutes, 
then electrophoresed on 10-15% polyacrylamide gels (PAGE). 
The contents of the gels were electro-transferred to 
nitrocellulose membranes and stained with a gold colloid stain 
to ascertain the protein content and purity. 
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Initial Guinea Pig Protection Tests 
Each of the 20 fractions was combined with an equal 
volume of aluminum hydroxide gel adjuvant and used to immunize 
groups of two guinea pigs. The guinea pigs received 2 doses 
{l ml/dose) at 3-week intervals. Fourteen days after the 
second dose, one of the two guinea pigs was challenged by 
injecting virulent c. chauvoei spores. Guinea pig deaths were 
recorded. Serum was collected from the second guinea pig in 
each group and used to identify protective immunogens through 
immunoblotting techniques . 
Purified Immunogen Protection Test 
One protein was chosen as a likely protective immunogen 
from the initial guinea pig test. The protein was purified by 
isoelectric focusing, followed by ultrafiltration through a 
300-Kd molecular weight cut-off {MWCO) filter . The protein 
was then dialyzed in a 50-Kd MWCO dialysis tubing. To 
validate the results of the initial guinea pig protection 
test, a group of 13 guinea pigs wase vaccinated twice with 100 
µg of purified soluble protein at 3-week intervals. Five 
nonvaccinated controls were also included in the test. Two 
weeks after the second injection, eight vaccinates and five 
controls were challenged with an injection of virulent 
c. chauvoei spore suspension. Serum was collected from the 
remaining five vaccinated guinea pigs and used to prepare 
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immunoblots. 
Immunoblots 
Precipitated protein from the culture supernatant and the 
purified immunogen were electrophoresed on 10% SOS-PAGE gels 
and electro-transferred to nitrocellulose membranes. 
Immunoblots were performed using serum collected from the 
guinea pigs in the guinea pig protection tests. Other 
immunoblots were made using serum from cattle and rabbits 
which had been vaccinated with c. chauvoei bacterin-toxoids. 
Amino Acid Sequencing 
The purified protein immunogen was separated by an 
initial preparative isoelectric focusing of the supernatant as 
described above, followed by electrophoresis on a 10 % native 
PAGE gel. The separated proteins were electro-transferred to 
a PVDF membrane. A portion of the membrane was used for amino 
acid analysis and N terminal amino acid sequencing . The 
sequence was compared to the GENE BANK data base using GCG 
software (Genetics Computer Group , Inc. , Madison, WI). 
Hemolysin Assay 
Samples of culture supernatant, precipitated culture 
supernatant as well as each isoelectric focused sample were 
assessed for hemolytic activity. Two-fold serial dilutions of 
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each of the samples were made in O.OlM PBS, starting at 1:2 
and ending at 1:1024. Fifty µl of each dilution was combined 
with 100 µl of a 1% suspension of bovine red blood cells in 
O.OlM PBS on a 96 well, round-bottomed microtitration plate. 
The plates were incubated at 37°C for two hours then 
transferred to a 4°C refrigerator for 12 hours. The titers 
were reported as the reciprocal of the highest dilution in 
which the red blood cells were completely hemolyzed. 
Hemolysin Inhibition Assay 
Pooled serum samples from groups of guinea pigs 
vaccinated with the purified soluble antigen, the purified 
flagellar antigen, and the whole culture bacterin-toxoid were 
assayed for their ability to neutralize the hemolytic activity 
of c. chauvoei culture supernatant . Two-fold serial dilutions 
of each serum sample were made in O. OlM PBS, starting at 
undiluted and ending at 1:1024 . Fifty µl of each dilution was 
combined with 50 µl of C. chauvoei culture supernatant and 
allowed to neutralize for 1 hour at room temperature. One 
hundred µl of a 1% suspension of bovine red blood cells were 
then added to each toxin-serum mixture . The 96 well, round-
bottomed microtitration plates which contained the mixtures 
were incubated at 37°C for two hours, then transferred to 4°C 
for an additional 12 hours. The antihemolytic titers were 
reported as the highest dilution of serum which completely 
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neutralized the hemolytic activity of the culture supernatant. 
Cellular Antigens 
Flagella 
Flagella were sheared from the cells by homogenizing the 
cell suspension for 5 min at 20,000 RPM in a high speed 
homogenizer. The flagella was purified by differential 
centrifugation and density gradient ultracentrifugation, as 
previously described. 6 The flagella was evaluated for purity 
using electron microscopy and SOS-PAGE. Cross-reactivity with 
other clostridial antigens was evaluated by enzyme-linked 
immunoassay (ELISA) using the partially purified flagella as 
the solid phase antigen. Mono-specific rabbit antiserum 
samples against c. novyi , c. perfringens types c and D, 
c. septicum, c. tetani, c. hemolyticum, and c. sordellii were 
tested for reactivity with flagellar protein. 
Further purification of the flagella was accomplished by 
isoelectric focusing of the crude f lagellar extract prior to 
density gradient ultracentrifugation. The technique for 
isoelectric focusing of the flagellar preparation was the same 
as that previously described for the soluble antigen. The 
flagella migrated to an isoelectric point at a pH of 
approximately 4.25 . 
Purified flagella was used to immunize a group of 13 
guinea pigs. The animals were given two 100-µg doses at 3-
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week intervals. Two weeks following the second vaccination, 
nine of the guinea pigs along with five nonvaccinated control 
animals were challenged with virulent spores of c. chauvoei. 
Serum was collected from the remaining four vaccinated guinea 
pigs for use in preparing immunoblots. 
Cell Wall Antigen 
Def lagellated whole cells were checked for cross-
reactivity among clostridial species using an indirect ELISA. 
Dilute whole cells were used as the solid-phase antigen and 
coated onto a microtitration plate. Mono-specific rabbit 
antiserum samples against the clostridial species used to test 
flagellar antigen were assayed. 
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RESULTS 
In the initial guinea pig protection test, animals 
vaccinated with soluble fractions having isoelectric points of 
4.25 and 4.74-5.15 all survived challenge. The immunoblots 
done with serum from the guinea pigs in this test indicated 
that, for the pI 4.74-5.15 samples, a protein with molecular 
mass of approximately 88 Kd was most likely responsible for 
conferring protective immunity (Figure 1). The fraction with 
a pI of 4.25 contained a protein band with a molecular mass of 
approximately 46 Kd. This pI and molecular mass are identical 
to that of the flagellar protein. None of the other fractions 
conferred protective immunity. 
In the second guinea pig protection test, the purified 
soluble protein protected six of eight vaccinated guinea pigs. 
All control guinea pigs died as a result of the challenge. 
Immunoblots of the soluble antigens made using serum from 
the guinea pigs that were vaccinated but not challenged, 
demonstrated that protected guinea pigs produced antibody to a 
single protein which had a molecular mass of approximately 88 
Kd and a pI of 4.96 (Figure 2). This protein was present in 
immunoblots made using serum from both the initial guinea pig 
protection test and the test using purified protein. No other 
single protein present in culture supernatant could be 
determined to be a protective immunogen from these tests; 
however, the fraction with a pI of 4.25 containing a 46 Kd and 
FIGURE 1: Immunoblots made using serum from guinea pigs 
vaccinated with separated soluble antigens . Each 
lane contains proteins with differing isoelectric 
points from c. chauvoei culture supernatant . 
Immunoblots were prepared using the serum from a 
guinea pig vaccinated with the corresponding 
fraction . Guinea p i gs vaccinated with fractions 1 
and 3 were not protected. The guinea pig 
vaccinated with fraction 2 (pI 4.25} was protected; 
guinea pigs vaccinated with fract i ons 4 (pI 4 . 74} 
and 5 (pI 4 . 80) survived challe nge but were very 
sick. Guinea pigs vaccinated with fractions 6 (pI 
4.91}, 7 (pI 5.03), and 8 (pI 5 . 15 } withstood 
challenge with no clinical signs . No other 
fractions demonstrated the 88 Kd protein in an 
immunoblot , and no other fract i ons were protective 
in guinea pigs. 
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FIGURE 2: Immunoblot made using serum from guinea pigs 
vaccinated with 88 Kd immunogen of Clostridium 
chauvoei. Lane A: Blank, Lane B: Precipitated 
toxin, Lane c: Purified 88 Kd immunogen, Lane D: 
Purified flagellar antigen. Serum from protected 
guinea pigs reacts almost exclusively with the 88 
Kd protein. 
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other proteins was protective. 
Immunoblots made using immune serum from rabbits and 
cattle demonstrated a major band at the 88-Kd molecular weight 
location (Figures 3 and 4). 
The results of the amino acid analysis of the 88 Kd 
protein are summarized in table 1. The following N terminal 
sequence was determined for the 88 Kd protective immunogen: 
Gly-Gly-Pro-Val-Gly-Leu-Leu-Gly-XXX-Thr-Arg 
This sequence was compared to the GENE BANK data base using 
the GCG computer program. No homologous or closely homologous 
sequences were found. 
The hemolytic activity of the supernatant, precipitated 
proteins from the supernatant, and the isoelectric focused 
fractions of the supernatant proteins are summarized in table 
2. The hemolytic activity of the supernatant remained with 
the precipitated proteins . The isoelectric focusing procedure 
significantly decreased the hemolyzing ability of the 
precipitate, however some hemolytic activity remained in 
fractions grouped around the isoelectric point of 5.90. 
The pooled serum samples from guinea pigs vaccinated with 
whole bacterin-toxoid had an anti-hemolysin titer of 32, while 
serum from guinea pigs vaccinated with both the purified 88 Kd 
immunogen as well as the flagellar antigen had no anti-
hemolysin titer. 
Electron micrographs of the partially purified flagella 
FIGURE 3: Immunoblot demonstrating antigens of c . chauvoei 
made using immune bovine serum from cattle 
vaccinated with a commercial bacterin-toxiod. Lane 
A: Purified flagella, Lane B: Precipitated 
supernatant , Lane C: Whole cells . All antigens of 
c . chauvoei are represented in the immunoblot . 
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FIGURE 4: Immunoblot demonstrating antigens of c. chauvoei 
made using immune rabbit serum from rabbits 
vaccinated with a commercial bacterin-toxoid . Lane 
A: Purified flagella, Lane B: Precipitated 
supernatant, Lane C: Whole cells. All antigens of 
c. chauvoei are represented in the immunoblot. 
37 
88Kd - -
46Kd -
A B c 
38 
TABLB 1: Amino acid analysis of 88 Kd protective immunoqen 
from the culture supernatant of c. chauvoei 
culture. a ,b 
Amino Acid 
Asparagine and Aspartic Acid 
Glutamine and Glutamic Acid 
Serine 
Glycine 
Histidine 
Arginine 
Threonine 
Alanine 
Pro line 
Tyrosine 
Valine 
Methionine 
Isoleucine 
Leucine 
Phenylalanine 
Lysine 
Mole % 
12.8 
9.0 
9 . 7 
12.5 
0.1 
1. 6 
8.6 
6.8 
2.5 
2.1 
7.6 
0.3 
7.9 
8.1 
3.2 
7.3 
NWllber of 
Amino Acids 
per Molecule 
114 
77 
81 
107 
1 
11 
63 
60 
29 
17 
66 
5 
67 
69 
28 
55 
a The amino acid analysis was done by the Iowa State 
b University Protein Facility. 
Tryptophan and cysteine not included in analysis. 
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TABLE 2: Isoelectric points and bemolysin titers of 
fractions of ciostridium chauvoei culture 
supernatant separated by isoelectric focusing. 
Fraction pH Hemolytic Titer 
Supernatant 6.8 32 
Precipitated protein 7 . 0 1024 
IEF Fraction # 1 . 3.98 4 
2 . 4.25 2 
3. 4 . 44 2 
4 . 4 . 74 2 
5 . 4 . 80 2 
6 . 4.91 2 
7 . 5 . 03 2 
8. 5 . 15 2 
9. 5.25 4 
10. 5.38 8 
11. 5 . 46 8 
12 . 5 . 54 8 
13 . 5 . 67 16 
14 . 5 . 73 32 
15 . 5 . 80 32 
16 . 5.90 64 
17. 5.99 64 
18. 6 15 32 
19. 6.45 16 
20. 6 . 78 8 
FIGURE 5: Scanning electron micrograph of partially purified 
flagella from Clostridium chauvoei cells (35,000X) . 
Some cellular debris is visible between the 
palisading flagellar f i brils . 
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revealed some cellular debris in the preparation {Figure 5). 
The material was confirmed as cellular debris by the presence 
of serological cross-reactivity with c. perfringens type C 
antiserum. Since c. perfringens is not flagellated, the 
cross-reactivity was most likely due to cellular components 
other than flagella. Further purification of the flagella by 
isoelectric focusing eliminated the cross-reactions and 
resulted in a pure flagella preparation as evidenced by single 
bands on SOS-PAGE gels. Purified flagella protected eight out 
of nine guinea pigs, while none of the non-vaccinated control 
animals survived challenge. Immunoblots made using the serum 
from guinea pigs vaccinated with purified flagella 
demonstrated the purity of the flagellar protein (Figure 6). 
Protein bands at 46 and 92 Kd were recognized by antibodies of 
protected guinea pigs. 
FIGURE 6: Immunoblot demonstrating the purity of the 
Clostridium chauvoei flagellar preparation. The 
blot was made using serum from guinea pigs 
vaccinated with the flagellar preparation. Lane A: 
Purified flagella, Lane B: Precipitated 
supernatant, Lane C: Whole cells. All antigens of 
c. chauvoei are represented in the three lanes. 
The 88 Kd band is visible in lane B even though the 
protein is not present in sufficient amount in lane 
A to be visible. 
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DISCUSSION 
Several investigations have been previously undertaken in 
an attempt to elucidate which immunogens of c. chauvoei are 
protective6'7'8 '11'12'16 • Partially purified flagella, which 
consisted of a mixture of proteins as demonstrated on SOS-PAGE 
gels, was shown to be protective in both guinea pigs and 
mice8'16 • However, other studies showed that flagella purified 
by enzymatic treatment or acid extraction are unable to 
produce protective immunity in guinea pigs6'7 • In an attempt to 
clarify these discrepant results, part of this study evaluated 
the ability of a highly purified flagellar preparation to 
induce protective immunity in guinea pigs . Interestingly, the 
serum from guinea pigs that had been vaccinated with purified 
flagella also contained antibody which reacted with the 88 Kd 
protein which was concentrated from culture supernatant. The 
88 Kd "soluble" antigen either has epitopes in common with 
flagella, or it is co-purified with the flagella. This raises 
the possibility that the 88-Kd protein may actually be part of 
the flagella since enough of this protein may be present in 
the pure f lagellar preparation to induce an immune response in 
guinea pigs; however, not enough is present to be detected on 
a stained SOS-PAGE gel or Western blot. It seems likely that 
a protein with a much higher isoelectric point and molecular 
weight would be separated by the f lagellar purification 
procedures unless it was physically linked to the flagellum. 
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This possibility may also explain previous discrepancies 
reported7'8 as to whether the cell wall or flagella contained 
the protective immunogen for c. chauvoei. If a protein at the 
base of the flagellum, such as the hook protein, were a 
protective immunogen, some of it would be separated along with 
the flagella, and some would remain in the cell wall. The 
supernatant would contain f lagellar proteins from dead and 
dying cells, which may dissociate . The 88-Kd protein is 
concentrated from the supernatant by precipitation and 
isoelectric focusing. This hypothesis would also be 
consistent with the observation that the soluble immunogen 
does not appear in the supernatant until very late in the 
growth cycle of the bacteria. 12 
Former investigations into the soluble immunogens of 
C h . 1 t . . . t t lt 10,11,12 . c auvoei a so con ain 1ncons1s en resu s . Data from 
this study demonstrated that anti-hemolytic activity of serum 
does not necessarily correlate to animal protection as 
10 reported by Bergman . Guinea pigs vaccinated with the 88 Kd 
protein were protected from challenge, however sera from those 
animals contained no anti-hemolytic activity. The hemolytic 
activity of the culture supernatant remained with the 
precipi tated fraction. Some hemolytic activity was lost in 
the isoelectric focusing procedure with the remaining activity 
focused around an isoelectric point of approximately 6.0 . 
Guinea pigs vaccinated with protein fractions containing 
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hemolysin were not protected from challenge. 
Deflagellated whole cells cross-reacted with antisera 
against c. perfringens and c. septicum. Since methods to 
separate the shared antigens from those unique to c. chauvoei 
were beyond the scope of this study, no further evaluation was 
conducted with the deflagellated whole cells. 
The flagellum of c. chauvoei is a protective immunogen in 
guinea pigs. The flagella can be purified to an extent which 
eliminates the cross-reactivity caused by cellular antigens 
shared with other clostridial species. The immune systems of 
rabbits, guinea pigs, and cattle all recognize similar 
antigens of c. chauvoei with the flagellar protein being a 
dominant antigen. The primary protein of the flagella is a 
molecule with molecular weight of approximately 46 Kd and an 
isoelectric point of 4.25. 
The culture filtrate of c. chauvoei contains a protein 
that is also a protective immunogen in guinea pigs . This 
protein has a molecular weight of approximately 88 Kd and an 
isoelectric point of 4.96. The tendency for this molecule to 
segregate with flagella during purification procedures as well 
as previous reports of protective immunity being induced by 
antigens located in the cell wall, leads to the speculation 
that it may be part of the flagellar base. Further studies 
are required to determine the cellular location and function 
of this molecule. 
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GENERAL SUMMARY 
Clostridium chauvoei is an important animal pathogen which 
causes a disease in cattle and sheep known as blackleg. 
Prevention of blackleg is routinely achieved by vaccination of 
susceptible animals. Vaccine manufacturers currently must 
test c. chauvoei bacterins by immunizing and challenging 
guinea pigs. An alternate potency test is desirable. Since 
many antigens in clostridial products are cross-reactive, an 
alternative test should measure the ability of a vaccine to 
induce an immune response directed only at protective 
immunogens of c. chauvoei. 
Controversy exists in the literature as to which 
immunogens of c. chauvoei are protective. Data from this 
project identified flagellar protein as being a protective 
immunogen in guinea pigs. Data also indicated that a protein 
found in culture supernatant, which has a molecular weight of 
88 Kd and a isoelectric point of 4.96, is also a protective 
immunogen in guinea pigs. This 88 Kd protein co-purifies 
with flagella and may be a flagella associated structural 
protein. Evidence was presented that demonstrated similar 
responses by the immune systems of rabbits and cattle to 
c . chauvoei antigens. Contrary to previous studies, data from 
this project showed that protective immunogens found in 
culture supernatant do not necessarily induce antihemolytic 
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antibodies. 
In the appendix of this thesis the procedure for a 
proposed alternative test for measuring the potency of 
vaccines containing C. chauvoei is outlined. This test 
measures the immune response of rabbits directed specifically 
toward flagellar antigen. 
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INTRODUCTION 
This appendix contains the instructions for carrying out 
an indirect Enzyme-Linked Immunosorbent Assay (ELISA) which 
compares the Clostridium chauvoei flagella-specific antibody 
content of a sample of pooled rabbit sera to a standard rabbit 
serum sample. The solid phase antigen used in this test is 
purified c. chauvoei flagella. Flagellar antigen was chosen 
over the 88 Kd antigen for this test for several reasons. 
Pilot studies performed in our laboratory indicated that 
f lagellar antigen was more stable than the 88 Kd antigen 
described in this thesis. Rabbits vaccinated with serials of 
fresh vaccine containing c. chauvoei produced antibodies to 
both the flagellar and 88 Kd antigen. However, when older 
vaccine was used to vaccinate rabbits, the antibody response 
to the 88 Kd antigen decreased in relation to the antibody 
response to the flagellar antigen. Also, flagella-specific 
diagnostic tests have been described in the literature making 
the flagella-based test more acceptable to industry. 
More than 1 antigen is probably involved in eliciting a 
protective immune response to c. chauvoei. The ELISA 
procedure that follows measures the antibody response of a 
group of rabbits to a single, specific immunogen. Attempting 
to correlate the potency of C. chauvoei vaccines to the immune 
response of rabbits to a single protein may prove to be 
futile. It does, however, appear to be a logical place to 
start. 
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SUPPLEMENTAL ASSAY METHOD FOR 
TESTING THE POTENCY 
OF PRODUCTS CONTAINING 
CLOSTRIDIUM CHAUVOEI ANTIGEN 
Clostridium chauvoei 
This test is used to determine the potency of products containing 
ClostridiUIJl chauvoei antigen . Rabbits are vaccinated twice 20 to 23 
days apart and bled 14 to 17 days following the second vaccination . 
The serum is assayed for C. chauvoei flagella - specific antibody by 
indirect enzyme-linked immunosorbent assay (ELISA) and compared to a 
reference rabbit serum sample using the USDA Relative Potency Program 
(current version). 
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B. TEST ANIMAL REQUIREMENTS 
Clos tridium chauvoei 
1. Nonpregnant New Zealand white rabbits weighing 4 to 8 pounds, free 
of external parasites , are used in this potency test . 
2. At least seven rabbits are vaccinated per serial. 
C. VACCINATION AND BLEEDING 
1. Each sample bottle of product is thoroughly shaken before the 
syringe is filled. 
2. Each rabbit is vaccinated subcutaneously in the shoulder region 
with one-half of the smallest host animal dose. 10-ml or 30-ml 
sterile disposable syringes with 20- gauge , 1-inch disposable 
needles are used. 
3. A second vaccination is given 20 to 23 days after the first 
vaccination. 
4. Fourteen to seventeen days after the second vaccination, rabbits 
are anesthetized with a mixture of xylazine and ketamine . The 
mixture is made by adding 3.6 ml xylazine (20 mg/ml) to 4.8 ml 
ketamine 
(100 mg/ml) . The rabbits are given 0 . 15 ml/kg of this mixture, 
intramuscularly . The rabbits are bled from the heart, using a 13 -
ml evacuated serum separation tube with a 20-gauge, l~-inch 
needle . Approximately 13 ml of blood is obtained from each 
rabbit . The rabbits are then euthanatized. The tubes of blood 
are gentl y inverted at least five times and held at room 
temperature until they are centrifuged (approximately 30 minutes) . 
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5. The tubes are centrifuged at 1000 x g for 10 to 20 minutes at 4• 
C. Sera are poured into labeled 16 x 125 mm screw-capped tubes. 
Equal volumes of serum from each rabbit vaccinated with the same 
serial of product are pooled in a 17 x 100 mm snap-capped tube . 
The pool must consist of sera from at least seven rabbits for a 
valid test . A sample of the pooled serum may be held at 4-8" C up 
to 7 days before the ELISA is run . The remaining serum is stored 
at - 20" C . 
D. ELISA REAGENTS AND MATERIAL 
l. Antigen Coating Buffer 
Deionized water 
0 . 80 g 
1.45 g 
500 ml 
The pH is adjusted to 9.6 using 5 M NaOH . The buffer is stored at 
4° C i n a sealed container for no longer than l week . 
2 . Antigen 
Clostridium chauvoei purified flagellar antigen (IRP 419), 
provided by the National Veterinary Services Laboratories (NVSL) , 
is used to coat the well surface of the microtitration plate . 
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NaCl 
N~P04~0 
NaJIP04 
Solution 
Deionized water 
Nonfat dry milk 
Tween 20 
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4 . 25 g 
0.10 g 
0 . 75 g 
500 ml 
5 g 
.25 ml 
Clostridium chauvoei 
The pH is adjusted to 7 . 9 with 5 M NaOH . The solution is stored 
at 4° C for no longer than 1 week . 
4. Wash Solution 
NaCl 
Tween 20 
Deionized water 
8 . 50 g 
0 . 25 g 
1.19 g 
0 . 50 ml 
1000 ml 
The pH is adjusted to 7.2 with 5 M NaOH . The solution is stored 
at 4° C for no longer than 4 weeks . 
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5. Serum and Conjugate Diluting Solution (SCDS ) 
NaCl 8 . 50 g 
N~P04·R:i0 0.25 g 
N~P04 1.19 g 
Nonfat dry milk 10 g 
Tween 20 1.0 ml 
Deionized water 1000 ml 
The pH is adjusted to 7 . 2 with 5 NaOH. The diluent is stored at 
4° C for no longer than 1 week . 
6 . Conjugate 
Peroxidase Conjugated Goat Anti-Rabbit IgG. 
7 . Substrate 
TMB (3,3'5 ,5'-tetramethylbenzidine) peroxidase substrate system, 
is purchased from Ki rkegaard & Perry Laboratories, Inc. , 2 Cessna 
Court , Gaithersburg, MD 20879 . (The use of this product by the 
NVSL is not an endorsement over other products not mentioned . ) 
8 . Stop Solution 
Stop solution is prepared by adding 24 . 5 ml R:iS04 to 70 ml of R:iO. 
The volume is then raised to 100 ml with R:iO . The stop solution 
may be stored at room temperature for an indefinite period of 
time . 
9 . Negative Serum 
Negative rabbit serum (IRP 420) from the NVSL is used i n the ELISA 
as a negative control . 
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10 . Reference Rabbit Serum 
Clostridium chauvoei 
Clostridium chauvoei positive rabbit serum (IRP 421) is provided 
by the NVSL . This reference was prepared from a serial of product 
with the minimum acceptable potency . 
D. ELISA PROCEDURE 
1 . Antigen Immobilization (Coating) 
a . Clostridium chauvoei purified flagella (IRP 419) is diluted in 
Antigen Coating Buffer according to instructions that 
accompany the antigen sent from the NVSL . 
b. 100 µl of diluted antigen is dispensed into each well of a 96 -
well microtitration plate . The plate is covered with a lid 
and placed in a humid atmosphere . 
c . The plate is incubated overnight a t 4 -8° C. All incubations 
are conducted with agitation on an orbital shaker revolving at 
120 cycles per minute . 
d . After the incubation period, the plate is inverted and shaken 
to remove excess antigen. 
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2. Blocking Well Surfaces 
a . Each well of the microtitration plate is filled with Blocking 
Solution (one plate requires approximately 40 ml of Blocking 
Solution) . 
b . The plate is covered and incubated in a humid atmosphere at 
35-37° C for 2 hours . 
c. The plate is inverted and shaken to remove excess blocking 
solution . The plate is sealed, placed in a plastic bag, and 
stored at 4° C in an inverted position. Plates can be stored 
for approxi mately 2 weeks. 
3 . Addition of Serum Samples 
a. The plate is removed from the plasti c bag, and each well is 
washed eight times using approximately 0 . 3 ml of wash solution 
per well . The inverted plate is tapped on absorbent material 
to remove all traces of residual wash solution. 
b . Negative rabb i t serum (!RP 420) , Clostri dium chauvoei positive 
rabbit serum (!RP 421), and test serial rabbit serum are all 
run on the same plate. Only absorbance readings generated 
from the same microtitration plate can be compared for 
relative potency . 
c. The serum samples are diluted 1 : 100 by adding 100 µl of serum 
to 9 . 9 ml SCDS . A noncoated microtitration plate is used to 
make serial two-fold dilutions starting with 1 : 200 . 125 µl of 
SCDS is added to each well in columns 2 through 11 . 125 µl of 
9CFR 113.106 
(Proposed) 
70 
SAM 200 
December 31. 1992 
Supersedes 
July 14, 1980 
Clostridium chauvoei 
the 1:100 dilutions of the serum samples is added to the 
corresponding well in the second col umn of the plate . Serial 
two - fold dilutions are made across the rows of the plate 
( starting with column 2) by transferring 125 µl from one well 
to the next through column eleven . 100 µl of each dilution is 
then transferred to the corresponding well on the antigen-
coated microtitration plate . The negative serum is placed in 
row A, the positive reference serum is p l aced in row B, and 
test sera are placed in rows C through G. Also, 100 µl SCDS 
is transferred to each well in column 1 . These wells are used 
to blank the microELISA autoreader . The remaining outside 
wells are not used. The desired dilution scheme on the seeded 
microtitration plate i s illustrated in Figure 1. 
d. The plate is covered and incubated in a humid atmosphere for 
1 hour at 35 -37" C. 
4 . Addition of Conjugate 
a . The plate is removed from the incubator and washed as 
previously described in D. 3 . a . 
b. Peroxidase conjugated anti-rabbit IgG is diluted in SCDS to 
approximately 1 : 4000 . 
c . 100 µl of diluted conjugate is added to each well of the 
plate . 
d . The plate is covered and incubated in a humid atmosphere at 
35 - 37° C for 1 hour . 
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5. Addition of Substrate 
Clostridium chauvoei 
a . The plate is removed from the incubator and washed as 
previously described in D.3.a . 
b. 6 . 0 ml of TMB peroxidase substrate is added to 6 . 0 ml of 
peroxidase solution B (~02) . 
c. 100 µl of substrate solution is dispensed into the wells of 
the plate, beginning with column l and continuing through 
column 12. 
d . The plate is covered and incubated at 20-24° C for 6-8 
minutes. 
6 . Addition of Stop Solution 
The reaction is stopped by adding 100 µl of stop solution to each 
well of the plate . (After stopping , the TMB substrate becomes 
yellow.) 
7 . Absorbance Readings 
The plates are read using an ELISA reader with dual wavelengths 
(450 nm test, 650 nm reference) . The mean optical density (O . D. ) 
for the blank wells is calculated . The blank mean 0 . D. is 
subtracted from each of the test well O. D. values before any dat a 
are analyzed. 
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E. DATA PROCESSING AND INTERPRETATION OF TEST RESULTS 
1 . Relative Potency Calculation Method 
The USDA Relative Potency Calculation Program is used to calculate 
the relative potency of the test serial compared to that of the 
reference . The reference and test serial data are entered, and 
the program is executed as outlined in SAM 318 (current version). 
The relative potency value (RP) reported for the test serial will 
be the highest RP of the top scores from each test . 
2. Requirements for a Valid Assay 
To be considered valid, an assay must meet all of the requirements 
of SAM 318 (current version), as well as requirements for a 
minimum slope and negative control . 
a . Lines determined by firs t order linear regression must have a 
correlation coefficient (r) ~ 0 . 95 . 
b . The reference line and the test serial line must show 
parallelism (slope ratio ~ 0 . 80) . 
c . All of the negative serum dilutions must have O. D. values 
under 0.2. 
d. Lines used in the relative potency calculation must have 
slopes with an absolute value greater than 0 . 2 . 
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Assays that do not contain valid lines may be repeated 
up to a maximum of three times. If a valid assay cannot 
be achieved with three independent assays , the serial 
will be reported as unsatisfactory . 
3. Requirements for a Satisfactory Serial 
To be considered satisfactory , a test serial must have an RP of~ 
1.0. Serials with an RP less than 1.0 on a valid assay may be 
retested by conducting up to a maximum of three independent 
replicate tests in a manner identical to the initial test . If 50 
percent or more of the highest RP values of all tests are ~ 1 . 0, 
the serial is satisfactory . 
